logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
Y

Yusuke Onozawa

Shizuoka Cancer Center
H指数:28
被引数:2,782

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and biomarker analysis for nivolumab in cancer of unknown primary: results from an investigator-initiated expanded access program

纳武利尤单抗治疗未知原发灶癌症的疗效与生物标志物分析：来自研究者发起的扩展性准入项目的结果

International Journal of Clinical Oncology
IF2.8
2026-09-240
OAAI
Junko Tanizaki; Kan Yonemori; Yuichi Takiguchi; Kohei Akiyoshi; Keigo Komine; Yusuke Onozawa; Mariko Sato; Kenro Hirata; Takuma Onoe; Ryotaro Ohkuma; Yosuke Horita; Hironobu Minami; Kazunori Honda; Koichi Suyama; Akihiko Ito; Yasutaka Chiba; Hiroko Watanabe; Yosuke Togashi; Kazuko Sakai; Kazuto Nishio; Kazuhiko Nakagawa; Hidetoshi Hayashi
Optimal number of needle passes in endoscopic ultrasound-guided tissue sampling for genomic profiling: a randomized, non-comparative trial

内镜超声引导下组织采样进行基因组分析的最佳穿刺次数：一项随机、非对照试验

Gastrointestinal Endoscopy
IF7.5
2025-06-280
PRE
Hirotoshi Ishiwatari; Kazuma Ishikawa; Junya Sato; Fumitaka Niiya; Hirofumi Yasui; Yusuke Onozawa; Kentaro Yamazaki; Akiko Todaka; Takahiro Tsushima; Satoshi Hamauchi; Tomoya Yokota; Takeshi Kawakami; Kotoe Oshima; Kunihiro Fushiki; Hiroki Sakamoto; Takuya Doi; Masahiro Yamamura; Tomoko Norose; Nobuyuki Ohike; Akifumi Notsu; Hiroyuki Ono
A phase II study of ME2136 (Asenapine Maleate) plus standard antiemetic therapy for patients, including diabetic patients, receiving cisplatin-based chemotherapy

ME2136 (马来酸阿塞那平) 加标准止吐治疗的II期研究，用于接受基于顺铂的化疗的患者，包括糖尿病患者

INVESTIGATIONAL NEW DRUGS
IF2.7
2024-10-260
PRE
Hamauchi, Satoshi; Yasui, Hirofumi; Yokota, Tomoya; Tsushima, Takahiro; Fushiki, Kunihiro; Naito, Tateaki; Ono, Akira; Kado, Nobuhiro; Onozawa, Yusuke; Murakami, Haruyasu; Takahashi, Toshiaki; Hirashima, Yasuyuki; Mori, Keita; Yamazaki, Kentaro
Incidence and risk factors associated with the development of hypothyroidism after postoperative chemoradiotherapy for head and neck cancer patients with high-risk features: Supplementary analysis of JCOG1008
ORAL ONCOLOGY
IF3.9
2024-10-011
PRE
Shimizu, Hidetoshi; Kodaira, Takeshi; Kiyota, Naomi; Hayashi, Ryuichi; Nishino, Hiroshi; Asada, Yukinori; Mitani, Hiroki; Hirayama, Yuuji; Onozawa, Yusuke; Nishio, Naoki; Hanai, Nobuhiro; Ohkoshi, Akira; Hara, Hiroki; Monden, Nobuya; Nagaoka, Masato; Minami, Shujiro; Fujii, Takashi; Tanaka, Kaoru; Homma, Akihiro; Yoshimoto, Seiichi; Oridate, Nobuhiko; Omori, Koichi; Ueda, Tsutomu; Okami, Kenji; Uemura, Hirokazu; Shiga, Kiyoto; Nakahira, Mitsuhiko; Asakage, Takahiro; Saito, Yuki; Sasaki, Keita; Kitabayashi, Ryo; Ishikura, Satoshi; Nishimura, Yasumasa; Tahara, Makoto
Nivolumab for cancer of unknown primary (CUP): Clinical efficacy and biomarker analysis from NivoCUP2 expanded access program (WJOG14620M)

纳武利尤单抗用于未知原发灶癌症（CUP）：来自纳武利尤单抗CUP2扩展性用药项目（WJOG14620M）的临床疗效与生物标志物分析

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Tanizaki, J.; Yonemori, K.; Takiguchi, Y.; Akiyoshi, K.; Komine, K.; Onozawa, Y.; Sato, M.; Hirata, K.; Onoe, T.; Ishiguro, T.; Ito, A.; Chiba, Y.; Watanabe, H.; Togashi, Y.; Sakai, K.; Nishio, K.; Nakagawa, K.; Hayashi, H.
Risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer receiving chemoradiotherapy: A re-analysis of a phase II/III JCOG1008 trial

头颈癌放化疗患者顺铂诱导急性肾损伤的风险预测模型: JCOG1008 II/III期试验的再分析

ORAL ONCOLOGY
IF3.9
2024-07-014
PRE
Imamura, Yoshinori; Kiyota, Naomi; Tahara, Makoto; Kodaira, Takeshi; Hayashi, Ryuichi; Nishino, Hiroshi; Asada, Yukinori; Mitani, Hiroki; Iwae, Shigemichi; Nishio, Naoki; Onozawa, Yusuke; Hanai, Nobuhiro; Ohkoshi, Akira; Hara, Hiroki; Monden, Nobuya; Nagaoka, Masato; Minami, Shujiro; Kitabayashi, Ryo; Sasaki, Keita; Homma, Akihiro

研究方向

暂未获取到该数据
H
Hirofumi Yasui
H 指数:33论文数:255被引数:4,876
T
Tomoya Yokota
H 指数:37论文数:345被引数:7,891
K
Kentaro Yamazaki
H 指数:46论文数:557被引数:1.4万
T
Takahiro Tsushima
H 指数:33论文数:252被引数:4,673
A
Akiko Todaka
H 指数:22论文数:173被引数:1,546
S
Satoshi Hamauchi
H 指数:20论文数:115被引数:1,128
A
Akira Fukutomi
H 指数:33论文数:227被引数:6,043
N
Nozomu Machida
H 指数:27论文数:269被引数:2,741
T
Takeshi Kawakami
H 指数:11论文数:164被引数:599
N
Narikazu Boku
H 指数:75论文数:815被引数:2.9万